A systems-level proteomic analysis identifies kinesin targets of KIFBP during neuronal development

Mapping the Regulatory Logic of Neuronal Motors

Neurons rely on a sophisticated internal logistics network to grow and maintain themselves. At the heart of this network are kinesins—molecular motor proteins that walk along microtubules (the cell's structural tracks) to transport vital cargo like vesicles and organelles. Scientists have long known that a regulator called KIFBP (kinesin family binding protein) acts as a brake for some of these motors. It prevents them from interacting with the tracks. Mutations in KIFBP are linked to Goldberg-Shprintzen Syndrome (GOSHS), a neurodevelopmental disorder involving intellectual disability and microcephaly.

While the connection between KIFBP and developmental defects is clear, the specific "traffic controllers" being managed remained a mystery. We knew KIFBP inhibited certain kinesins, but we did not know which ones were active during the critical window of neuronal differentiation (the process where stem cells become specialized neurons). Nor did we have a clear map of the full regulatory network. This study uses a systems-level proteomics approach (the large-scale study of proteins) to identify the specific kinesin targets that KIFBP governs as neurons develop.

The missing links in the kinesin interactome

Current understanding of KIFBP is largely built on studies in non-neuronal cell lines like HEK293 or HeLa. While these provided a foundation, they fall short of capturing the complexity of a developing brain. Kinesin activity is highly context-dependent. A motor that is abundant in a skin cell might be nearly absent in a maturing neuron. Consequently, looking at KIFBP through the lens of generic cell lines leaves us blind to the specific regulatory events that drive neurite outgrowth (the growth of long, branch-like projections from a neuron).

The authors argue that to understand the pathology of GOSHS, we must observe KIFBP in action during actual neuronal differentiation. Previous cellular studies had even reported conflicting results regarding how KIFBP levels affect neurite length. This suggests that the relationship is not a simple "more is better" equation. Instead, it is a delicate balance that varies by cell type. Without a specialized model and a comprehensive proteomic map, the specific kinesins driving these morphological changes remained unidentified.

Decoding the KIFBP interactome

To solve this, the researchers established a robust model using N2A-A5 mouse neuroblastoma cells. They first validated that these cells could be induced to differentiate into neuron-like cells through serum reduction and retinoic acid treatment. They observed significant increases in neurite length and differentiation markers [Figure 1A-C]. By performing bulk RNA sequencing (a method to measure gene activity), the authors confirmed that this differentiation involves a massive shift in the transcriptional landscape. This includes the upregulation of key kinesins like KIF5A and KIF3A [Figure 1D-F].

The core of their methodology relied on a multi-step biochemical and imaging pipeline:

1. System Establishment: The team generated a CRISPR-Cas9 KIFBP knockout (a method to disable a specific gene) N2A-A5 cell line. They found that without KIFBP, neurite extension is significantly impaired. This resulted in shorter average lengths and fewer differentiated cells [Figure 2B-D].
2. Proteomic Mapping: To find the targets, they used an inducible GFP-tagged KIFBP system. Through affinity purification coupled with mass spectrometry (IP-MS)—a technique that "fishes" for proteins physically bound to a specific target—they identified 338 interacting proteins. This group included 15 distinct kinesins [Figure 3E-F].
3. Single-Molecule Verification: Because binding does not always equal functional regulation, the authors moved to TIRF (total internal reflection fluorescence) microscopy. This allows researchers to watch individual motor proteins move along microtubules in real-time. By using purified KIFBP and motor domains tagged with mNeonGreen, they could directly measure whether KIFBP actually stopped the motors from walking.

New targets and selective inhibition

The study's most striking result is the discovery that KIFBP is a highly selective regulator. The authors report that KIFBP can discriminate between very closely related motor proteins. For instance, in their motility assays, KIFBP dramatically reduced the directed movement of KIF5A. However, it had no effect on the motility of its relative, KIF5C [Figure 4A]. This specificity suggests that KIFBP is a precision tool. It manages specific subsets of motors during neurodevelopment.

Beyond confirming known targets like KIF13B and KIF18A, the paper identifies KIF5A and KIF18B as previously unrecognized regulatory targets [Figure 3F, Table 1]. The researchers demonstrate that KIFBP directly inhibits the motility of these motors in vitro (in a controlled environment outside a living organism). Interestingly, the study also highlights that KIFBP acts as a general inhibitor for both the kinesin-3 and kinesin-8 families. This expands the known scope of its regulatory reach. However, the authors note that not all kinesins identified in the mass spectrometry screen are inhibited. Motors like KIF4 and the kinesin-11 family (KIF26A/B) continue to move normally even in the presence of KIFBP [Figure 4D-E].

Boundaries of the proteomic map

While this study provides a much clearer map of the KIFBP interactome, it is not exhaustive. A significant limitation is the inability to fully characterize the kinesin-2 family (KIF3A/B/C). Although the IP-MS data showed KIFBP associates with these proteins, the authors could not perform motility assays on them. They faced technical difficulties in generating the necessary motile, dimeric (two-part) versions of these motors for the TIRF setup.

Furthermore, the study focuses on the immediate physical interactome. While the researchers identified 15 kinesins that associate with KIFBP, the biological consequence of every single interaction remains unproven. For example, while they identified KIF26A as a binder, they did not perform the single-molecule assays required to confirm if KIFBP actually inhibits its motility. This leaves a gap between "binding" and "functional regulation" for several candidates. Finally, as an in vitro and cell culture study, the findings lack the spatial complexity of a living brain. The precise timing and localization of these interactions in a developing embryo remain theoretical.

The verdict: A new blueprint for neurodevelopment

The researchers have successfully provided a much-needed toolkit for studying KIFBP-related disorders. By establishing the N2A-A5 cell line and mapping the KIFBP-kinesin network, they have moved the field toward identifying specific molecular culprits. The discovery of KIF5A and KIF18B as novel targets is a significant contribution. This likely shifts how we model the axonal transport failures seen in Goldberg-Shprintzen Syndrome.

Is this ready for clinical application? Not yet. This is foundational mechanistic work. However, for researchers investigating neurodevelopmental pathologies, this paper provides a definitive starting point. The identification of KIFBP's selectivity—specifically its ability to distinguish between KIF5A and KIF5C—is vital. It opens the door for future studies into how subtle changes in motor protein activity can lead to profound neurological consequences.

Figures from the paper